Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 154

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 154
---
 —

    3,976

    Total current liabilities

    15,551

    10,727

    Noncurrent operating lease liability

    31

    85

    Deferred grant liability

    —

    1,924

    Total liabilities

    15,582

    12,736

    Commitments and contingencies (Note 7)

    Stockholders’ equity (deficit):

    Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952   shares issued and outstanding as of December 31, 2024 and 2023

    —

    —

    Common stock, $0.001 par value; 100,000,000 shares authorized;  6,154,758 shares issued and 5,896,333 outstanding as of December 31, 2024, 4,522,656  shares issued and 4,444,097 outstanding as of December 31, 2023, respectively

    6

    5

    Treasury stock (at cost, 258,425 and 78,559 shares as of December 31, 2024 and 2023, respectively)

    (500
    )

    (126
    )

    Additional paid-in capital

    485,024

    479,274

    Accumulated deficit

    (493,479
    )

    (480,501
    )

    Total stockholders’ equity (deficit)

    (8,949
    )

    (1,348
    )

    Total liabilities and stockholders’ equity (deficit)
     
    $
    6,633

    $
    11,388

See Accompanying Notes to these Consolidated Financial Statements

77 

PLUS THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS 

(in thousands, except share and per share data)

    For the Years Ended December 31,

    2024

    2023

    Grant revenue
     
    $
    5,824

    $
    4,913

    Operating expenses:

    Research and development

    10,580

    9,690

    General and administrative

    9,939

    8,544

    Total operating expenses

    20,519

    18,234

    Operating